91 related articles for article (PubMed ID: 975074)
1. Antitumor activity of 9-hydroxyellipticine (NSC 210717) ON L1210 mouse leukemia and the effect of route of injection.
Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Cros S; Paoletti C
Cancer Res; 1976 Sep; 36(9 pt.1):3067-76. PubMed ID: 975074
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice.
Brassinne C; Atassi G; Frühling J; Penasse W; Coune A; Hildebrand J; Ruysschaert JM; Laduron C
J Natl Cancer Inst; 1983 Jun; 70(6):1081-6. PubMed ID: 6574278
[TBL] [Abstract][Full Text] [Related]
3. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
4. Effects of ellipticine on cell survival and cell cycle progression in cultured mammalian cells.
Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
Cancer Res; 1980 Jul; 40(7):2390-9. PubMed ID: 6155993
[TBL] [Abstract][Full Text] [Related]
5. Influence of inducers of monooxygenases on cytotoxic efficiency of ellipticine on leukemia L1210 cells.
Lesca P; Monsarrat B; Cros S; Paoletti C
J Natl Cancer Inst; 1981 Oct; 67(4):871-6. PubMed ID: 6944554
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane(isocitrato)platinum(II).
Macquet JP; Cros S; Armand JP
Cancer Res; 1984 Sep; 44(9):3736-43. PubMed ID: 6540142
[TBL] [Abstract][Full Text] [Related]
7. [Cytogenetic characteristics of the leukemia L1210 strain in the development of drug resistance].
Goncharova SA; Minenkova EA; Fomina MM; Demidova NS
Eksp Onkol; 1984; 6(4):38-41. PubMed ID: 6499750
[TBL] [Abstract][Full Text] [Related]
8. Effects of new antitumor bifunctional intercalators derived from 7H-pyridocarbazole on sensitive and resistant L 1210 cells.
Esnault C; Roques BP; Jacquemin-Sablon A; Le Pecq JB
Cancer Res; 1984 Oct; 44(10):4355-60. PubMed ID: 6467197
[TBL] [Abstract][Full Text] [Related]
9. Ellipticine, 9-hydroxyellipticine, and 9-hydroxyellipiticinum: some biochemical properties of possible pharmacologic significance.
Paoletti C; Auclair C; Lesca P; Tocanne JF; Malvy C; Pinto M
Cancer Treat Rep; 1981; 65 Suppl 3():107-18. PubMed ID: 7049365
[TBL] [Abstract][Full Text] [Related]
10. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
Kim K; Blechman WJ; Riddle VG; Pardee AB
Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
[TBL] [Abstract][Full Text] [Related]
11. [2 new antineoplastic derivatives: 9-hydroxy-2-methyl-ellipticinium (acetate) and 9-hydroxy-2,6-dimethyl-ellipticinium (chloride). Effect on mouse L 1210 leukemia].
Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Paoletti C
C R Acad Hebd Seances Acad Sci D; 1975 Nov; 281(18):1365-7. PubMed ID: 815025
[TBL] [Abstract][Full Text] [Related]
12. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
Woodman RJ
Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
[No Abstract] [Full Text] [Related]
14. Predictive values of the in vivo diffusion chamber for cyclophosphamide treatment of L1210 murine leukemia.
Anderson KC; Humphrey RL; Sensenbrenner LL
Cancer Res; 1983 May; 43(5):2030-3. PubMed ID: 6831434
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
Sirotnak FM; Donsbach RC; Moccio DM; Dorick DM
Cancer Res; 1976 Dec; 36(12):4679-86. PubMed ID: 1087182
[TBL] [Abstract][Full Text] [Related]
16. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
17. Combination antifol therapy: observations on the development of resistant L1210 leukemic cells in vivo.
Browman GP; Lazarus H
Cancer Treat Rep; 1980; 64(2-3):231-6. PubMed ID: 7407755
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of novel octalactin A analogs in murine leukemia cells in vitro.
Perchellet JP; Perchellet EM; Newell SW; Freeman JA; Ladesich JB; Jeong Y; Sato N; Buszek K
Anticancer Res; 1998; 18(1A):97-106. PubMed ID: 9568062
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of antitumor activity of vincristine by the biscoclaurine alkaloid cepharanthine.
Kato T; Suzumura Y
J Natl Cancer Inst; 1987 Sep; 79(3):527-32. PubMed ID: 3476792
[TBL] [Abstract][Full Text] [Related]
20. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
